INSUBCONTINENT EXCLUSIVE:
Lucence Diagnostics, a genomic medicine startup that develops non-invasive tests for cancer screening, announced today that it has raised a
Other participants included SGInnovate and returning investors Heliconia Capital (a subsidiary of Temasek Holdings), Lim Kaling and Koh Boon
North America.The funding will also support two prospective clinical trials
for early-stage detection in several types of cancer, including lung, colorectal, breast and pancreatic
Lucence is currently designing a study that will involve 100,000 participants to validate its early-stage detection test
It will recruit its first patient in the middle of next year and launch in the United States and Asia.Together with its seed funding, this
Kong, and it plans to expand further in North America and East Asia
Its lab in Singapore has received both CLIA certification and CAP accreditation, which means its tests can be used by doctors and patients
It is also currently building a lab in the Bay Area to decrease turnaround times for patients.Headquartered in Singapore, with offices in
San Francisco, Hong Kong and Suzhou, China, Lucence was founded by CEO Dr
The company says LiquidHALLMARK has been used by oncologists for 1,000 patients in Asia so far.Other genomic sequencing startups that have
developed tests that screen for cancer risks and signs include Sanomics, Prenetics, Guardant and Grail
mutations linked to cancer
monitoring.In a statement, Dr
better, value-driven outcomes through precise treatment selections and more affordable care
